Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, rangi ...

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.10 per share when it actually produced a loss of $0.10, delivering no surprise.Over the last four quarters, the company h ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 Arbutus Biopharma Corporation (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 98-0597776 (State or Other ...

EXHIBIT 99.2 Corporate Presentation NASDAQ: ABUS www.arbutusbio.com January 13, 2025 © 2025 Arbutus Biopharma, Inc. Forward-Looking Statements Arbutus Biopharma (ABUS) Overview Focused on Developing a Functional Cure for Patients with Chronic HBV Leveraging virology expertise and proven track record in success to address global health issue. HBV Represents a Large Commercial Opportunity ~250M¹ people have cHBV with current treatment options for most patients limited to life-long suppressive therapy, represe ...

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 2025 Reviewing pipeline and development plans for HBV programs Continued focus on efficient deployment of financial resources and personnel – terminated ATM program and implemented reduction of workforce by 57% in Q1 2025 Board has approved further changes to executive leadership team; including the appointment of ...

Core Viewpoint - Genevant Sciences and Arbutus Biopharma have filed five international lawsuits against Moderna, seeking to enforce patents related to their lipid nanoparticle (LNP) technology, alleging infringement in 30 countries [1][2]. Group 1: Legal Actions - The lawsuits aim to obtain monetary relief and injunctions against Moderna's Spikevax and other products that allegedly utilize the same LNP technology [2]. - The enforcement actions cover multiple jurisdictions, including Austria, Belgium, France, Germany, Italy, Spain, and Turkey, among others [3]. - In addition to international lawsuits, there is an ongoing case in the U.S. District Court for the District of Delaware, with a jury trial scheduled for September 2025 [4]. Group 2: Technology Background - The LNP technology developed by Arbutus and Genevant is crucial for the effective delivery of mRNA to human cells, addressing significant technological challenges in mRNA medicine development [5]. - This technology involves microscopic particles made from four types of fat-like molecules, which protect mRNA and facilitate its delivery to target cells [5]. - Genevant has over 20 years of experience in LNP delivery technology, which has been licensed for various applications, including vaccines and gene editing [6]. Group 3: Company Profiles - Genevant Sciences is recognized for its robust LNP patent portfolio and has pioneered LNP delivery for over two decades, enabling a wide range of RNA-based applications [6]. - Arbutus Biopharma focuses on infectious diseases and is developing treatments for chronic hepatitis B, while also leveraging its partnership with Genevant to maximize the potential of LNP technology [8].

WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D., M.B.A., as Chief Executive Officer. Ms. Androski replaces Michael J. McElhaugh, the Company’s Interim President and CEO, effective immediately. Ms. Androski will also serve as a member of the Company’s board of dire ...

Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon WARMINSTER, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced its 2025 corporate objectives an ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will participate in the virtual H.C Wainwright @ Home fireside chat series taking place on Tuesday, December 3, 2024 at 11:00 am ET. To access the live webcast of the fireside ...